Healthcare / Medical DevicesStockholm
$0.97
-0.07 (-6.73%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-9.4M · quality 42.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
9/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$55M
P/E
N/A
•EV/EBITDA
13.9x
↑ROE
-32.6%
↓Gross Margin
76.1%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+2.3%
FCF CAGR
—
FCF margin
-15.2%
FCF / Net income
0.64x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $61.8M · net income $-14.6M · FCF $-9.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $61.8M | $61.8M | $60.4M | $61.5M | $57.7M |
| Net Income | $-14.6M | $-14.6M | $327000.00 | $-9.1M | $-7.3M |
| EBITDA | $2.5M | $2.5M | $-11.2M | $-3.0M | $-2.6M |
| EPS | -0.32 | -0.32 | 0.01 | -0.20 | -0.18 |
| Gross Margin | 76.1% | 76.1% | 76.5% | 86.0% | 83.1% |
| Operating Margin | -21.8% | -21.8% | -13.5% | -13.4% | -13.2% |
| Net Margin | -23.7% | -23.7% | 0.5% | -14.8% | -12.7% |
| Balance Sheet | |||||
| Current Ratio | 1.44 | 1.44 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-9.4M | $-9.4M | $-1.5M | $-16.3M | $-2.3M |
| Returns | |||||
| ROE | -32.6% | -32.6% | 0.7% | -21.9% | -19.7% |
| Valuation | |||||
| P/E | — | — | 172.00 | — | — |
| EV/EBITDA | 13.86 | 13.86 | — | — | — |
| P/B | 0.98 | 0.98 | 1.78 | 2.30 | 2.60 |
| Growth & Yield | |||||
| Revenue Growth | 2.3% | 2.3% | -1.8% | 6.7% | — |
| EPS Growth | -3300.0% | -3300.0% | 105.0% | -11.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-27.3%
Start / end P/E
n/dx → n/dx
EPS bridge
0.01 → -0.32
Residual
-27.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.